LeonaBio, Inc. (LONA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LeonaBio, Inc. (LONA) has a cash flow conversion efficiency ratio of -0.424x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.90 Million) by net assets ($49.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of LeonaBio, Inc. to measure how many days the company can operate on defensive assets alone.
LeonaBio, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how LeonaBio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
LeonaBio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LeonaBio, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
G8 Education Ltd
AU:GEM
|
0.097x |
|
Mirae Asset Daewoo Co Ltd
KO:006805
|
-0.323x |
|
Emerita Resources Corp
V:EMO
|
-0.014x |
|
Oil Terminal C
RO:OIL
|
0.008x |
|
Quality Construction Products Public Company Limited
BK:Q-CON
|
0.032x |
|
Rangdong Light source and Vacuum flask JSC
VN:RAL
|
0.223x |
|
Solitario Exploration & Royalty Corp
NYSE MKT:XPL
|
-0.019x |
|
Pathfinder Bancorp Inc
NASDAQ:PBHC
|
-0.003x |
Annual Cash Flow Conversion Efficiency for LeonaBio, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of LeonaBio, Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see LeonaBio, Inc. (LONA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.79 Million | $-45.73 Million | -1.646x | +24.06% |
| 2024-12-31 | $44.84 Million | $-97.17 Million | -2.167x | -180.01% |
| 2023-12-31 | $130.19 Million | $-100.75 Million | -0.774x | -151.11% |
| 2022-12-31 | $235.14 Million | $-72.47 Million | -0.308x | -129.61% |
| 2021-12-31 | $321.08 Million | $-43.10 Million | -0.134x | -52.68% |
| 2020-12-31 | $274.28 Million | $-24.11 Million | -0.088x | -146.70% |
| 2019-12-31 | $-19.72 Million | $-3.71 Million | 0.188x | -37.48% |
| 2018-12-31 | $-14.89 Million | $-4.48 Million | 0.301x | -- |
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment o… Read more